Sera Prognostics (NASDAQ:SERA) and Cardio Diagnostics (NASDAQ:CDIO) Critical Review

Cardio Diagnostics (NASDAQ:CDIO) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.

Risk & Volatility

Cardio Diagnostics has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.

Profitability

This table compares Cardio Diagnostics and Sera Prognostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-40,543.75%	-89.41%	-82.81%
Sera Prognostics	-34,866.67%	-52.54%	-36.97%

Insider and Institutional Ownership

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by company insiders. Comparatively, 11.3% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Cardio Diagnostics and Sera Prognostics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10,000.00	559.44	-$6.50 million	($2.53)	-0.75
Sera Prognostics	$80,000.00	991.18	-$31.93 million	($0.67)	-3.00

Cardio Diagnostics has higher earnings, but lower revenue than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Cardio Diagnostics and Sera Prognostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1	0	0	0	1.00
Sera Prognostics	1	0	1	1	2.67

Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 173.63%. Given Sera Prognostics’ stronger consensus rating and higher possible upside, analysts clearly believe Sera Prognostics is more favorable than Cardio Diagnostics.

Summary

Sera Prognostics beats Cardio Diagnostics on 12 of the 15 factors compared between the two stocks.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care. The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.

About Sera Prognostics

Sera Prognostics, Inc. is a women’s health company focused on identifying pregnancy risks through blood-based testing and biomarker research. The company develops diagnostic products intended to help healthcare providers assess pregnancy outcomes and support individualized care. Its lead product, the PreTRM test, analyzes proteins in a pregnant patient’s blood to estimate the risk of spontaneous preterm birth. The company has developed the test for use by healthcare providers in the United States and continues to study its potential role in pregnancy care.